Soleno down after Scorpion Capital remains short

** Shares of drugmaker Soleno Therapeutics SLNO.O fall 1.1% to $68.87

** Scorpion Capital says it remains short on Soleno, alleging that "insiders appear a lot less bullish about their drug's prospects than investors"

** The US FDA approved Soleno's rare genetic disorder drug, Vykat XR, to treat Prader-Willi syndrome in March

** Earlier this month, Scorpion Capital alleged that the drug causes high risk of fluid buildup in the lungs and heart failure, adding that drug "may be at risk of being withdrawn from market"

** Including session moves, stock up 53.3% YTD